Exelixis
EXELExelixis Inc is a fully integrated oncology company focused on the discovery, development, and commercialization of next-generation cancer treatments.
Earnings
Next report
Nov 3, 2026 (in 2 months)Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Exelixis Inc is a fully integrated oncology company focused on the discovery, development, and commercialization of next-generation cancer treatments. The company leverages its expertise in small molecules and biotherapeutics, such as antibody-drug conjugates, to address high unmet medical needs in various solid tumors. Its core value proposition is built on its flagship tyrosine kinase inhibitor franchise and a growing pipeline of clinically differentiated assets.
A leading oncology-focused biotechnology company with a dominant position in the renal cell carcinoma market through its cabozantinib franchise.
FAQ
- What is Exelixis's market cap?
- Exelixis (EXEL) has a market capitalization of $14.1B and trades on NASDAQ.
- What is Exelixis's revenue and profitability?
- Exelixis generated $2.4B in trailing twelve-month revenue with net income of $860.6M, representing a net margin of 35.3%. Gross margin stands at 96.5%, with free cash flow of $1.2B. The latest reported period is Q2 2026.
- Who are Exelixis's competitors?
- Exelixis's key competitors include Eli Lilly, Pfizer, Karyopharm Therapeutics Inc., and others. These companies compete in similar markets and product categories.
- Who does Exelixis partner with?
- Exelixis's notable partners include Ipsen, Takeda Pharmaceutical Company, Bristol-Myers Squibb, and others.
- Where is Exelixis headquartered?
- Exelixis is headquartered in United States of America and employs approximately 1,310 people. It has been publicly traded since 2000.
